Glycogen Synthase Kinase 3: A Point of Integration in Alzheimer's Disease and a Therapeutic Target? — Siddhartha Mondragón‐Rodríguez (2012) | RDL Network
Glycogen synthase kinase 3 (GSK3) has been implicated in neurological disorders; therefore, it is not surprising that there has been an increased focus towards developing therapies directed to this kinase. Unfortunately, these current therapies have not taken into consideration the physiological role of GSK3 in crucial events like synaptic plasticity. With this in mind we will discuss the relationship of synaptic plasticity with GSK3 and tau protein and their role as potential targets for the development of therapeutic strategies. Finally, we will provide perspectives in developing a cocktail therapy for Alzheimer's treatment.
Anta Ngkelo, Roland F. Hoffmann, Andrew Durham, John A. Marwick, Simone Brandenburg, Harold G. de Bruin, Marnix R. Jonker, Christos Rossios, Eleni Tsitsiou, Gaetano Caramori, Marco Contoli, Paolo Casolari, Francesco Monaco, Filippo Andò, G Speciale, Iain Kilty, Kian Fan Chung, Alberto Papi, Mark A. Lindsay, Nick H.T. ten Hacken, Maarten van den Berge, Wim Timens, Peter J Barnes, Antoon J. van Oosterhout,
Discussion(0)
No comments yet. Be the first to comment.